NCT06172751View on ClinicalTrials.gov

TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause

CompletedOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

April 26, 2024

Study Completion Date

April 26, 2024

Conditions
Hypereosinophilic Syndrome (HES)
Interventions
OTHER

no intervention

not applicable, this is an observational retrospective data analysis study; no interventions in the study

OTHER

no intervention

not applicable, this is an observational retrospective data analysis study; no interventions in the study

Trial Locations (1)

02140

Research Site, Cambridge

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY